Irritable Bowel Syndrome and Digestive Health Support Forum banner
1 - 10 of 10 Posts

·
Registered
Joined
·
550 Posts
Discussion Starter · #1 ·
Here is yet one more new drug in phase II. The trial is recruiting in Canada and in the state of Minnesota here in the US. Like many other studies, this one is also only recruiting women.http://www.clinicaltrials.gov/ct/show/NCT00399438?order=9This drug is a CRF-1 antagonist also in phase II for depression and anxiety. It is interesting to see BMS study this one for IBS-D, as GSK is studying their CRF-! antagonist in all subtypes.Here is about all I could find on this drug, called BMS-562086.http://neurotransmitter.net/newdrugs.html
 

·
Registered
Joined
·
550 Posts
Discussion Starter · #2 ·
Here is a brand new article on CRF antagonists for IBS. Despite the medical jargon I think most people should be able to get the gist of it and it looks promising.http://www.ncbi.nlm.nih.gov/entrez/query.f...l=pubmed_docsumIt looks like this article was funded by AstraZeneca so maybe they too will join Bristol-Myers and Glaxo in developing what might be the future of IBS treatment.
 

·
Registered
Joined
·
108 Posts
JJ - Thanks for tracking down and posting this great info. I remember hearing about CRF antagonists at the UNC patient symposium back in July. Dr. Whitehead called this the hottest new area in IBS reserach, but I wasn't sure what drugs, if any, were currently in the pipeline. So if some of these are in Phase II right now, any guess as to the soonest they could be approved and available? Two, three, four years?? Or longer? Tim
 

·
Registered
Joined
·
550 Posts
Discussion Starter · #4 ·
Hey Tim,First of all, a big THANK YOU for having the cojones to come out and bring attention to our cause with your book. I read the excerpts on your blog and also listened to your radio interview. I also remember your summary of the UNC Patient Symposium very well. Thanks for posting it.Anyway, with regard to your question, I suppose 2 years might be a bit optimistic but hopefully within 4 years we might be seeing some of these drugs if all goes well. So far, it seems like the only companies studying these drugs for IBS are Bristol-Myers Squibb and GlaxoSmithKline (see my post in "News, Research, and Abstracts" if you're interested.)One thing I've noticed is that these companies are taking a very cautious approach, with both GSK and BMS doing small phase IIa and exploratory studies.Another thing I've tried to emphasize in some of my recent posts is the possibility of using drugs off-label that are or were in development for IBS but are further along in clinical development for other conditions. For example, Sanofi-Aventis has two different antidepressants in phase III, one an NK-2 antagonist and the other a beta-3 adrenergic agonist, both of which have some possibility of effectiveness in IBS. With regard to the CRF antagonists, both Pfizer and Janssen are studying this type of drug for anxiety and depression, and may well jump on the bandwagon of studying them for IBS as well. But my point here is that IBS patients should try these drugs as soon as they come to market regardless of what indication they are approved for. A lot of people with IBS also have anxiety and depression (as if I really needed to remind anyone), so it wouldn't even technically be off-label use. The downside is that no CRF antagonist seems to be beyond phase II for any indication, which means a few years of waiting at least.
 

·
Registered
Joined
·
108 Posts
Hey, thanks for the supporitve feedback. Very much appreciated!So when you say it will be possible for some of these drugs to be used "off-label," I'm guessing that's similar to how anti-anxiety meds like Xanax or TCAs like Elavil can help with IBS symptoms? Even though this stuff is still several years off (and that's IF things go well), I think it's extremely encouraging to see that the drug companies 1) are taking our condition seriously, and 2)are even this far along in developing and testing these new drugs. Thanks again for staying on top of all this for us.Tim
 

·
Registered
Joined
·
550 Posts
Discussion Starter · #6 ·
Tim,No problem. And yes, you're right. It would be pretty much exactly like using Elavil, Xanax, etc.Anyway, I did a bit more poking around on Clincaltrials.gov and turned up the following:pfizer's CRF-1 antagonist, CP-316,311, has completed at least one phase II study for depression:http://www.clinicaltrials.gov/ct/show/NCT00143091?order=5The phase II drug from BMS (the original topic of this thread), BMS-562086, is still recruiting in phase II for depression. The study started almost exactly a year ago, so hopefully they are making good progress.http://www.clinicaltrials.gov/ct/show/NCT00135421?order=3GSK/Neurocrine's drug, GW876008, is only just starting phase II for anxiety. It is also in phase II for IBS.http://www.clinicaltrials.gov/ct/show/NCT00397722?order=2http://www.clinicaltrials.gov/ct/show/NCT00385099?order=3It seems like these are probably the drugs to watch for now. I looked up some of the others from the Neurotransmitter.net table that were in phase I or preclinical but there was no record of them. In any case those are much further from market.So right now it looks like Pfizer is probably in the lead. This drug, if the trial was successful, could be heading to phase III but also possibly phase IIb. Drug companies sometimes split-up phase II into A and B, I can only assume to minimize cost/risk. Unfortunately, that also slows the process down. In any case I will definitely be keeping tabs on it.
 

·
Registered
Joined
·
133 Posts
JJohnson....I remember calling this company three years ago about getting into their phase one trials but was unable to do so....They have been working on this drug for a while, and when I stopped seeing any information on the drug I figured it kind of went bust, but I am very glad to see they are finally making it to a phase 3 clinical trial with the new logistical and financial backing that I suppose they needed help with from GSK.....keeping my fingers crossed on this one....thanks for the heads up......
 

·
Registered
Joined
·
550 Posts
Discussion Starter · #9 ·
Hey Noguts,Which drug were you referring to? Sorry if this thread is getting a bit confusing, but the GSK/Neurocrine and Bristol-Myers drugs are only in phase II and are being studied for IBS. The Pfizer drug is only being studied for depression and MAYBE is heading to phase III, though based on the mode of action it might be an effective treatment for IBS.Actually, Pfizer just announced today that it would start making its drug development more transparent by listing its pipeline on its website. That should hopefully make following the development of their CRF antagonist much easier (if the phase II trial was successful and there is any development to follow, that is), as the company has been pretty secretive in the past. Hopefully we will also find out about this drug that Pfizer was developing for IBS in phase II but have had no recent update on.http://www.clinicaltrials.gov/ct/show/NCT00139672?order=33
 

·
Registered
Joined
·
550 Posts
Discussion Starter · #10 ·
Here is a very recent article originally from the Wall Street Journal on experimental drugs for depression that devotes a fair amount of attention to CRF antagonists. Although it doesn't discuss the use of these drugs in IBS, it does talk about some of the development hurdles these drugs have faced and what their prospects might be, so thought this may be of interest to some people here.http://www.post-gazette.com/pg/06348/746134-114.stm
 
1 - 10 of 10 Posts
This is an older thread, you may not receive a response, and could be reviving an old thread. Please consider creating a new thread.
Top